311 related articles for article (PubMed ID: 38048782)
21. CAR T cells and checkpoint inhibition for the treatment of glioblastoma.
Shen SH; Woroniecka K; Barbour AB; Fecci PE; Sanchez-Perez L; Sampson JH
Expert Opin Biol Ther; 2020 Jun; 20(6):579-591. PubMed ID: 32027536
[No Abstract] [Full Text] [Related]
22. Glioblastoma Immune Landscape and the Potential of New Immunotherapies.
Daubon T; Hemadou A; Romero Garmendia I; Saleh M
Front Immunol; 2020; 11():585616. PubMed ID: 33154756
[TBL] [Abstract][Full Text] [Related]
23. Local immunotherapy of glioblastoma: A comprehensive review of the concept.
Sabahi M; Salehipour A; Bazl MSY; Rezaei N; Mansouri A; Borghei-Razavi H
J Neuroimmunol; 2023 Aug; 381():578146. PubMed ID: 37451079
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy: a promising approach for glioma treatment.
Yasinjan F; Xing Y; Geng H; Guo R; Yang L; Liu Z; Wang H
Front Immunol; 2023; 14():1255611. PubMed ID: 37744349
[TBL] [Abstract][Full Text] [Related]
25. The Role of Checkpoint Inhibitors in Glioblastoma.
Desai K; Hubben A; Ahluwalia M
Target Oncol; 2019 Aug; 14(4):375-394. PubMed ID: 31290002
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy in Glioblastoma: A Clinical Perspective.
Desbaillets N; Hottinger AF
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359621
[TBL] [Abstract][Full Text] [Related]
27. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
28. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
Lin H; Liu C; Hu A; Zhang D; Yang H; Mao Y
J Hematol Oncol; 2024 May; 17(1):31. PubMed ID: 38720342
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapeutic Approaches for the Treatment of Glioblastoma Multiforme: Mechanism and Clinical Applications.
Das S; Dash BS; Premji TP; Chen JP
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445721
[TBL] [Abstract][Full Text] [Related]
30. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
Kiyokawa J; Kawamura Y; Ghouse SM; Acar S; Barçın E; Martínez-Quintanilla J; Martuza RL; Alemany R; Rabkin SD; Shah K; Wakimoto H
Clin Cancer Res; 2021 Feb; 27(3):889-902. PubMed ID: 33257429
[TBL] [Abstract][Full Text] [Related]
31. Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models.
Koch MS; Zdioruk M; Nowicki MO; Griffith AM; Aguilar E; Aguilar LK; Guzik BW; Barone F; Tak PP; Tabatabai G; Lederer JA; Chiocca EA; Lawler S
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017150
[TBL] [Abstract][Full Text] [Related]
32. Current State of Immunotherapy for Treatment of Glioblastoma.
McGranahan T; Therkelsen KE; Ahmad S; Nagpal S
Curr Treat Options Oncol; 2019 Feb; 20(3):24. PubMed ID: 30790064
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy for glioblastoma: the promise of combination strategies.
Bausart M; Préat V; Malfanti A
J Exp Clin Cancer Res; 2022 Jan; 41(1):35. PubMed ID: 35078492
[TBL] [Abstract][Full Text] [Related]
34. Current Advances in Immunotherapy for Glioblastoma.
Mende AL; Schulte JD; Okada H; Clarke JL
Curr Oncol Rep; 2021 Jan; 23(2):21. PubMed ID: 33496872
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy for Neuro-Oncology.
Majd N; Dasgupta P; de Groot J
Adv Exp Med Biol; 2020; 1244():183-203. PubMed ID: 32301015
[TBL] [Abstract][Full Text] [Related]
36. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
Desland FA; Hormigo A
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
[TBL] [Abstract][Full Text] [Related]
37. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
[TBL] [Abstract][Full Text] [Related]
38. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
Zhang P; Zhang Y; Ji N
Front Immunol; 2022; 13():927132. PubMed ID: 35874698
[TBL] [Abstract][Full Text] [Related]
39. Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations.
Niedbała M; Malarz K; Sharma G; Kramer-Marek G; Kaspera W
Onco Targets Ther; 2022; 15():437-468. PubMed ID: 35509452
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy for Glioblastoma: Current Progress and Challenges.
Yu MW; Quail DF
Front Immunol; 2021; 12():676301. PubMed ID: 34054867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
